Jonathan Edwards

Professor Jonathan Edwards is an Emeritus Professor of Connective Tissue Medicine at University College London (UCL) in the UK. Professor Edwards was instrumental in the discovery of the use of B-cell depletion therapy (Rituximab) to treat rheumatoid arthritis.

B-cell Depletion ME/CFS Research
Professor Edwards became interested in the possible use of Rituximab to treat ME/CFS after attending the Invest in ME International ME Conference in May 2013 and subsequently agreed to advise on and lead the effort.

Phoenix Rising
Professor Edwards once served on the board of directors of the online patient community Phoenix Rising. He is active in its online forums.

Science for ME
Professor Edwards is currently active on the Science for ME forum.

Open Letters to The Lancet
In response to The Lancet 's publication of the controversial PACE trial in 2011, three open letters to the editor of The Lancet urged the editor, Richard Horton, to commission a fully independent review of the PACE trial. Dr. Edwards signed all three. The first, written in 2015, was signed by Dr. Edwards and five of his colleagues. In 2016, thirty-six additional colleagues in the ME/CFS field, signed the second letter. In 2018, a resubmitted letter had over one hundred signatories.
 * 13 November 2015, An open letter to Dr. Richard Horton and The Lancet
 * 10 February 2016, An open letter to The Lancet, again - Virology blog
 * 9 July 2018, Yet Another Appeal to The Lancet, With More On Board

Publications Related to ME/CFS

 * 2016, The biological challenge of myalgic encephalomyelitis/chronic fatigue syndrome: a solvable problem, Editorial by Jonathan C.W. Edwards, Simon McGrath, Adrian Baldwin, Mark Livingstone & Andrew Kewley (Full Text)
 * 2017, PACE team response shows a disregard for the principles of science in Journal of Health Psychology (Full Text)

Talks & Interviews

 * 30 May 2014, Keynote Speaker at the 9th Invest in ME International ME Conference - DVD available
 * 3 Sept 2013, Interview: Professor Jonathan Edwards on the UK Rituximab trial